Desmopressin (
DDAVP) is commonly used for treatment and prevention of
bleeding complications in patients with
bleeding disorders including
haemophilia A,
von Willebrand's disease (VWD) and other less common disorders. This article reviews the current evidence for the use of
DDAVP in pregnancy to clarify its efficacy and safety with regard to maternal and foetal outcome. A search of the literature found 30 studies that reported
DDAVP use in pregnancy for prophylaxis or treatment of
bleeding complications with 216 pregnancies reported in total. The most common indication was prophylaxis for prevention of
bleeding during pregnancy and postpartum haemorrhage.
DDAVP was used successfully in the first and early second trimester for
bleeding prophylaxis in 50 pregnancies. No postpartum
bleeding complications were reported in 167 out of 172 pregnancies when
DDAVP was used for peripartum haemostatic cover. Twenty-nine studies reported no significant adverse events as a result of treatment with
DDAVP. One case of
water intoxication seizure and one case of premature labour following the use of
DDAVP was reported in a single study. Other maternal side effects included facial
flushing and
headache and were reported by one study. These side effects were generally well tolerated by patients. There were no other significant adverse events reported in any of the studies as a result of
DDAVP use. Foetal outcome was recorded in ten studies with no adverse foetal outcomes. In conclusion, this review shows that
DDAVP in selected cases is effective in reducing
bleeding complications associated with pregnancy and childbirth with a good safety record. Further research is needed to confirm these findings as they are based on the currently available evidence from small studies and case series only.